Avidity Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Avidity Biosciences (Nasdaq: RNA) announced its participation in two key investor conferences: the 2022 Wells Fargo Healthcare Conference on September 7 at 1:20 pm ET and the Chardan 6th Annual Genetic Medicines Conference on October 4 at 11:30 am ET. Interested parties can access live webcasts and replays via Avidity's 'Events and Presentations' page. The company focuses on innovative RNA therapeutics, specifically Antibody Oligonucleotide Conjugates (AOCs™), with three programs expected in clinical development by the end of 2022, including AOC 1001 for myotonic dystrophy.

SAN DIEGO, Sept. 1, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Avidity management team will be participating at the following upcoming conferences:

• 2022 Wells Fargo Healthcare Conference on Wednesday, September 7 at 1:20pm ET
• Chardan 6^th Annual Genetic Medicines Conference on Tuesday, October 4 at 11:30am ET

Live webcasts of each event, up-to-date event details and an archived replay of the webcasts following each event, will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.

About Avidity

Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity's proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity is on track to have three programs in clinical development by the end of 2022. The company's lead product candidate, AOC 1001, is designed to treat patients with myotonic dystrophy type 1 (DM1). AOC 1001 is currently in Phase 1/2 development with the ongoing MARINA™ trial and MARINA-OLE™ in adults with DM1. The next programs in the company's advancing and expanding pipeline are AOC 1044, the lead of three programs for the treatment of DMD, and AOC 1020, designed to treat people living with FSHD. Avidity anticipates both programs will enter the clinic by the end of 2022. Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is headquartered in San Diego, CA. For more information about our science, pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and Twitter.

Company Contact:
Kath Gallagher
kath.gallagher@aviditybio.com
(858) 401-7900

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conferences-301616170.html

SOURCE Avidity Biosciences, Inc.

FAQ

What conferences will Avidity Biosciences participate in September 2022?

Avidity Biosciences will participate in the 2022 Wells Fargo Healthcare Conference on September 7 at 1:20 pm ET.

When is the Chardan 6th Annual Genetic Medicines Conference?

The Chardan 6th Annual Genetic Medicines Conference is scheduled for October 4, 2022, at 11:30 am ET.

What is the focus of Avidity Biosciences?

Avidity Biosciences focuses on RNA therapeutics, specifically Antibody Oligonucleotide Conjugates (AOCs™), targeting previously untreatable diseases.

What is AOC 1001 and its purpose?

AOC 1001 is Avidity's lead candidate designed to treat myotonic dystrophy type 1 and is in Phase 1/2 development.

How can I access Avidity's conference webcasts?

Live webcasts of Avidity's conference presentations will be available on their 'Events and Presentations' page on their website.